Institutional investors purchased a net $1.5 million shares of RGEN during the quarter ended September 2016 and now own 94.62% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CONESTOGA CAPITAL ADVISORS LLC Bought 25.1 Thousand shares of Repligen Corp
SHELL ASSET MANAGEMENT COMPANY B... Bought 16.7 Thousand shares of Repligen Corp
NNIP ADVISORS BV Bought 715.00 shares of Repligen Corp